<p>StockNews.com 的研究分析师在周日发布的报告中开始覆盖 Cytosorbents（NASDAQ:CTSO - 获取免费报告）的股票。该经纪公司对这家医疗研究公司的股票设定了 “持有” 评级。</p>
<p>其他几位股票分析师最近也对 CTSO 发布了报告。D. Boral Capital 在周五的研究报告中重申了 “买入” 评级，并对 Cytosorbents 的股票设定了 10.00 美元的目标价。HC Wainwright 在 11 月 11 日的研究报告中重申了 “中性” 评级，并对 Cytosorbents 的股票设定了 1.00 美元的价格目标。两位研究分析师对该股票给予了持有评级，两位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识价格目标为 4.67 美元。</p>
<p><strong>获取我们对 CTSO 的最新分析</strong></p>
<h2>Cytosorbents 股票上涨 1.8%</h2>
<p>Cytosorbents 股票在周五开盘价为 0.94 美元。Cytosorbents 的 52 周低点为 0.70 美元，52 周高点为 1.59 美元。该公司的市值为 5121 万美元，市盈率为 -2.60，贝塔值为 0.58。该公司的 50 日移动平均价格为 0.92 美元，200 日移动平均价格为 1.02 美元。公司的速动比率为 1.58，流动比率为 1.97，债务与股本比率为 1.06。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近对 CTSO 的持仓进行了调整。Atomi Financial Group Inc. 在第三季度收购了 Cytosorbents 的新头寸，价值 51,000 美元。Geode Capital Management LLC 在第三季度增加了对 Cytosorbents 股票的持股，增幅为 7.5%。Geode Capital Management LLC 目前拥有 467,058 股该医疗研究公司的股票，价值 701,000 美元，此前在上个季度又购买了 32,415 股。最后，Sargent Investment Group LLC 在第二季度将其在 Cytosorbents 股票中的持仓提高了 4.9%。Sargent Investment Group LLC 目前拥有 1,433,500 股该医疗研究公司的股票，价值 1,008,000 美元，此前在上个季度又购买了 67,181 股。对冲基金和其他机构投资者持有该公司 32.87% 的股票。</p>
<h2>Cytosorbents 公司简介</h2>
<p>(获取免费报告)</p>
<p>Cytosorbents Corporation 从事医疗设备的研究、开发和商业化，其血液净化技术平台结合了专有的吸附剂和多孔聚合物技术，业务遍及美国、德国及国际市场。其旗舰产品为 CytoSorb，一种用于脓毒症治疗的体外细胞因子吸附器，作为辅助治疗，适用于其他重症护理应用、预防和治疗围手术期并发症，以及维持或增强从供体处采集的实质器官的质量以进行器官移植；并提供 VetResQ，一种用于动物脓毒症、胰腺炎和其他危重疾病的辅助治疗设备。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，胜过 Cytosorbents</li>
<li>为什么投资高收益分红股票？</li>
<li>量子机会：Skywater Technology 的长期潜力</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>Nebius Group：人工智能基础设施的新星</li>
<li>除了喝咖啡，还有 3 种投资咖啡的方法</li>
<li>MarketBeat 周回顾 – 12/30 - 1/03</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<p>→ 特朗普故意推动此加密货币上涨（来自 Crypto 101 Media）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTA4Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTA4Ng"/></p>
<h2>你现在应该投资 1,000 美元在 Cytosorbents 吗？</h2>
<p>在你考虑 Cytosorbents 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Cytosorbents 并不在名单上。</p>
<p>虽然 Cytosorbents 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CTSO

<p>Cytosorbents（纳斯达克代码：CTSO）获得了 StockNews.com 的 “持有” 评级，该机构对该股票进行了覆盖。其他分析师的意见各不相同，D. Boral Capital 给予 “买入” 评级，目标价为 10 美元，而 HC Wainwright 则设定了中性评级，目标价为 1 美元。该股票开盘价为 0.94 美元，52 周区间为 0.70 美元至 1.59 美元。机构投资者持有该公司 32.87% 的股份，该公司专注于血液净化的医疗设备</p>

<p>Research analysts at StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a report released on Sunday. The brokerage set a &#34;hold&#34; rating on the medical research company's stock.</p>
<div class="lb-trans"><p>StockNews.com 的研究分析师在周日发布的报告中开始覆盖 Cytosorbents（NASDAQ:CTSO - 获取免费报告）的股票。该经纪公司对这家医疗研究公司的股票设定了 “持有” 评级。</p>
</div><p>Several other equities analysts have also recently issued reports on CTSO. D. Boral Capital reiterated a &#34;buy&#34; rating and issued a $10.00 target price on shares of Cytosorbents in a research note on Friday. HC Wainwright reiterated a &#34;neutral&#34; rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $4.67.</p>
<div class="lb-trans"><p>其他几位股票分析师最近也对 CTSO 发布了报告。D. Boral Capital 在周五的研究报告中重申了 “买入” 评级，并对 Cytosorbents 的股票设定了 10.00 美元的目标价。HC Wainwright 在 11 月 11 日的研究报告中重申了 “中性” 评级，并对 Cytosorbents 的股票设定了 1.00 美元的价格目标。两位研究分析师对该股票给予了持有评级，两位给予了买入评级，一位给予了强烈买入评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “适度买入”，共识价格目标为 4.67 美元。</p>
</div><p><strong>Get Our Latest Analysis on CTSO</strong></p>
<div class="lb-trans"><p><strong>获取我们对 CTSO 的最新分析</strong></p>
</div><h2>Cytosorbents Stock Up 1.8 %</h2>
<div class="lb-trans"><h2>Cytosorbents 股票上涨 1.8%</h2>
</div><p>Cytosorbents stock opened at $0.94 on Friday. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59. The firm has a market cap of $51.21 million, a price-to-earnings ratio of -2.60 and a beta of 0.58. The business's 50-day moving average price is $0.92 and its 200 day moving average price is $1.02. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.</p>
<div class="lb-trans"><p>Cytosorbents 股票在周五开盘价为 0.94 美元。Cytosorbents 的 52 周低点为 0.70 美元，52 周高点为 1.59 美元。该公司的市值为 5121 万美元，市盈率为 -2.60，贝塔值为 0.58。该公司的 50 日移动平均价格为 0.92 美元，200 日移动平均价格为 1.02 美元。公司的速动比率为 1.58，流动比率为 1.97，债务与股本比率为 1.06。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in CTSO. Atomi Financial Group Inc. acquired a new position in Cytosorbents during the third quarter worth $51,000. Geode Capital Management LLC increased its stake in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Sargent Investment Group LLC raised its position in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company's stock worth $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对 CTSO 的持仓进行了调整。Atomi Financial Group Inc. 在第三季度收购了 Cytosorbents 的新头寸，价值 51,000 美元。Geode Capital Management LLC 在第三季度增加了对 Cytosorbents 股票的持股，增幅为 7.5%。Geode Capital Management LLC 目前拥有 467,058 股该医疗研究公司的股票，价值 701,000 美元，此前在上个季度又购买了 32,415 股。最后，Sargent Investment Group LLC 在第二季度将其在 Cytosorbents 股票中的持仓提高了 4.9%。Sargent Investment Group LLC 目前拥有 1,433,500 股该医疗研究公司的股票，价值 1,008,000 美元，此前在上个季度又购买了 67,181 股。对冲基金和其他机构投资者持有该公司 32.87% 的股票。</p>
</div><h2>Cytosorbents Company Profile</h2>
<div class="lb-trans"><h2>Cytosorbents 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.</p>
<div class="lb-trans"><p>Cytosorbents Corporation 从事医疗设备的研究、开发和商业化，其血液净化技术平台结合了专有的吸附剂和多孔聚合物技术，业务遍及美国、德国及国际市场。其旗舰产品为 CytoSorb，一种用于脓毒症治疗的体外细胞因子吸附器，作为辅助治疗，适用于其他重症护理应用、预防和治疗围手术期并发症，以及维持或增强从供体处采集的实质器官的质量以进行器官移植；并提供 VetResQ，一种用于动物脓毒症、胰腺炎和其他危重疾病的辅助治疗设备。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Cytosorbents</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Quantum Opportunity: Skywater Technology's Long-Term Potential</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>Nebius Group: The Rising Star in AI Infrastructure</li>
<li>3 Ways To Invest In Coffee, Other Than Drinking It</li>
<li>MarketBeat Week in Review – 12/30 - 1/03</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Cytosorbents</li>
<li>为什么投资高收益分红股票？</li>
<li>量子机会：Skywater Technology 的长期潜力</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>Nebius Group：人工智能基础设施的新星</li>
<li>除了喝咖啡，还有 3 种投资咖啡的方法</li>
<li>MarketBeat 周回顾 – 12/30 - 1/03</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><p>→ Trump’s Sending THIS Crypto Higher on Purpose (From Crypto 101 Media)(Ad)</p>
<div class="lb-trans"><p>→ 特朗普故意推动此加密货币上涨（来自 Crypto 101 Media）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMTA4Ng" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=11086&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Cytosorbents right now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cytosorbents 吗？</h2>
</div><p>Before you consider Cytosorbents, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cytosorbents 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Cytosorbents 并不在名单上。</p>
</div><p>While Cytosorbents currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cytosorbents 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Cytosorbents（纳斯达克代码：CTSO）被 StockNews.com 的分析师给予持有评级